On Oct 23, major Wall Street analysts update their ratings for $Regeneron Pharmaceuticals (REGN.US)$, with price targets ranging from $1,050 to $1,242.
Morgan Stanley analyst Terence Flynn maintains with a buy rating, and maintains the target price at $1,235.
Barclays analyst Carter Gould maintains with a buy rating, and adjusts the target price from $1,220 to $1,080.
Wells Fargo analyst Mohit Bansal maintains with a buy rating, and adjusts the target price from $1,200 to $1,050.
TD Cowen analyst Tyler Van Buren maintains with a buy rating, and maintains the target price at $1,230.
Piper Sandler analyst Christopher Raymond maintains with a buy rating, and maintains the target price at $1,242.
Furthermore, according to the comprehensive report, the opinions of $Regeneron Pharmaceuticals (REGN.US)$'s main analysts recently are as follows:
The adjustment of Eylea estimates is due to the Pavblu generic introduction, with a slight reduction in Dupixent estimates for the second half of 2024. Nonetheless, it's believed that the stock's previous concerns are mitigated, presenting a more favorable outlook leading up to imminent catalysts.
With Regeneron failing to obtain a stay against the Eylea biosimilar from Amgen, it is believed that an Amgen launch could happen soon. Nevertheless, it is considered that Regeneron still presents a buying opportunity in light of the recent decline in its stock.
Here are the latest investment ratings and price targets for $Regeneron Pharmaceuticals (REGN.US)$ from 6 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
